Literature DB >> 10843656

Cutting edge: CD46, a new costimulatory molecule for T cells, that induces p120CBL and LAT phosphorylation.

A Astier1, M C Trescol-Biémont, O Azocar, B Lamouille, C Rabourdin-Combe.   

Abstract

The widely expressed transmembrane molecule CD46 is the complement regulatory receptor for C3b as well as the receptor for several pathogens. Beside its binding functions, CD46 is also able to transduce signals. We showed that CD46 aggregation on human T cells induces p120CBL and linker for activation of T cells (LAT) phosphorylation. These two proteins are adaptor proteins known to regulate TCR signaling. p120CBL is a complex adaptor protein involved in negatively regulating signaling events, whereas LAT is a transmembrane adaptor protein found in glycolipid-enriched microdomains essential for T cell activation. Therefore, we investigated if a CD46/TCR costimulation would affect T cell activation. Indeed, CD46/CD3 costimulation strongly promotes T cell proliferation. Therefore, we propose that CD46 acts as a potent costimulatory molecule for human T cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843656     DOI: 10.4049/jimmunol.164.12.6091

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  CD46 engagement on human CD4+ T cells produces T regulatory type 1-like regulation of antimycobacterial T cell responses.

Authors:  Steven M Truscott; Getahun Abate; Jeffrey D Price; Claudia Kemper; John P Atkinson; Daniel F Hoft
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

Review 2.  T-cell stimulation and regulation: with complements from CD46.

Authors:  Claudia Kemper; James W Verbsky; Jeffrey D Price; John P Atkinson
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Ligation of the cell surface receptor, CD46, alters T cell polarity and response to antigen presentation.

Authors:  Jane Oliaro; Anupama Pasam; Nigel J Waterhouse; Kylie A Browne; Mandy J Ludford-Menting; Joseph A Trapani; Sarah M Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

4.  Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation.

Authors:  Winfried Barchet; Jeffrey D Price; Marina Cella; Marco Colonna; Sandra K MacMillan; J Perren Cobb; Paul A Thompson; Kenneth M Murphy; John P Atkinson; Claudia Kemper
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

5.  Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling.

Authors:  Karen Bieback; Egil Lien; Ingo M Klagge; Elita Avota; Jürgen Schneider-Schaulies; W Paul Duprex; Herrmann Wagner; Carsten J Kirschning; Volker Ter Meulen; Sibylle Schneider-Schaulies
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  CD46-utilizing adenoviruses inhibit C/EBPbeta-dependent expression of proinflammatory cytokines.

Authors:  Milena Iacobelli-Martinez; Ronald R Nepomuceno; Jodi Connolly; Glen R Nemerow
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Presenilin/gamma-secretase cleaves CD46 in response to Neisseria infection.

Authors:  Nathan J Weyand; Christine M Calton; Dustin L Higashi; Kristen J Kanack; Magdalene So
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

8.  RNA interference screen in primary human T cells reveals FLT3 as a modulator of IL-10 levels.

Authors:  Anne L Astier; Gaëlle Beriou; Thomas M Eisenhaure; Stephen M Anderton; David A Hafler; Nir Hacohen
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

Review 9.  T-cell regulation by CD46 and its relevance in multiple sclerosis.

Authors:  Anne L Astier
Journal:  Immunology       Date:  2008-04-02       Impact factor: 7.397

10.  CD46-induced human Treg enhance B-cell responses.

Authors:  Anja Fuchs; John P Atkinson; Veronique Fremeaux-Bacchi; Claudia Kemper
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.